Literature DB >> 20965467

Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis.

Nobuyoshi Tanaka1, Mitsuyasu Terashima, Sudhir Rathore, Tsuyoshi Itoh, Maoto Habara, Kenya Nasu, Masashi Kimura, Tatsuya Itoh, Yoshihisa Kinoshita, Mariko Ehara, Etsuo Tsuchikane, Keiko Asakura, Yasushi Asakura, Osamu Katoh, Takahiko Suzuki.   

Abstract

OBJECTIVES: We performed this study to investigate with optical coherence tomography (OCT) the vascular response after sirolimus-eluting stent (SES) implantation between patients with and those without diabetes mellitus (DM).
BACKGROUND: The difference in vascular response after SES implantation between patients with and those without DM has not been fully evaluated with OCT.
METHODS: Optical coherence tomography was performed to examine 74 nonrestenotic SES implanted in 63 patients (32 with DM and 31 without DM) at 9 months after SES implantation. For struts showing neointimal coverage, the neointimal thickness on the luminal side of each strut section was measured, and neointimal characteristics were classified into high, low, and layered signal pattern.
RESULTS: Baseline patient characteristics and lesion and procedural characteristics data were similar between the 2 groups. In total, 11,422 struts were analyzed. High signal neointima was observed in 90.2 ± 13.9%, low signal neointima in 7.3 ± 10.0%, and layered neointima in 2.7 ± 5.8%/stents. There was higher incidence of low signal neointima (10.5 ± 10.3% vs. 4.5 ± 5.6%, p = 0.003), neointimal thickness was larger (median: 106.8 μm, interquartile range: 79.3 to 130.4 μm vs. median: 83.5 μm, interquartile range: 62.3 to 89.3 μm; p < 0.0001), and neointimal coverage of stent struts was higher (92.1 ± 6.2% vs. 87.2 ± 11.9%; p = 0.03) in DM patients.
CONCLUSIONS: High signal neointimal pattern was predominantly observed, and low or layered signal pattern was observed in some cases. In DM patients, low signal neointima was observed with high frequency. Neointimal coverage and neointimal thickness was also higher in DM patients as compared with non-DM patients.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965467     DOI: 10.1016/j.jcin.2010.08.006

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  13 in total

1.  Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction.

Authors:  Hideki Yano; Shigeo Horinaka; Manami Watahik; Tomoko Watanabe; Toshihiko Ishimitsu
Journal:  Heart Vessels       Date:  2018-11-03       Impact factor: 2.037

2.  Complete disappearance of red thrombi in a drug-eluting stent despite discontinuation of antiplatelet therapy: Angioscopic confirmation.

Authors:  Daisuke Murakami; Masamichi Takano; Masanori Yamamoto; Nobuaki Kobayashi; Shinya Yokoyama; Yoshihiko Seino; Kyoichi Mizuno
Journal:  J Cardiol Cases       Date:  2011-11-03

3.  Early vascular responses after everolimus-eluting stent implantation assessed by serial observations of intracoronary optical coherence tomography.

Authors:  Hideki Yano; Shigeo Horinaka; Mayuko Ishikawa; Toshihiko Ishimitsu
Journal:  Heart Vessels       Date:  2017-02-14       Impact factor: 2.037

Review 4.  Left Main Coronary Artery Disease in Diabetics: Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting?

Authors:  Logan Disney; Chandrashekhar Ramaiah; Meghna Ramaiah; Suresh Keshavamurthy
Journal:  Int J Angiol       Date:  2021-08-31

Review 5.  Coronary artery revascularization in patients with diabetes mellitus.

Authors:  Ehrin J Armstrong; John C Rutledge; Jason H Rogers
Journal:  Circulation       Date:  2013-10-08       Impact factor: 29.690

Review 6.  Percutaneous coronary intervention in patients with diabetes: current concepts and future directions.

Authors:  Ehrin J Armstrong; Johannes Waltenberger; Jason H Rogers
Journal:  J Diabetes Sci Technol       Date:  2014-02-05

7.  Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial.

Authors:  Juan Luis Gutiérrez-Chico; Robert Jan van Geuns; Evelyn Regar; Willem J van der Giessen; Henning Kelbæk; Kari Saunamäki; Javier Escaned; Nieves Gonzalo; Carlo di Mario; Francesco Borgia; Eveline Nüesch; Héctor M García-García; Sigmund Silber; Stephan Windecker; Patrick W Serruys
Journal:  Eur Heart J       Date:  2011-06-09       Impact factor: 29.983

Review 8.  The role of optical coherence tomography in coronary intervention.

Authors:  Mitsuyasu Terashima; Hideaki Kaneda; Takahiko Suzuki
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

9.  Efficacy of Zotarolimus-Eluting Stents in Treating Diabetic Coronary Lesions: An Optical Coherence Tomography Study.

Authors:  Zhengbin Zhu; Jinzhou Zhu; Run Du; Haotian Zhang; Jinwei Ni; Weiwei Quan; Jian Hu; Fenghua Ding; Zhenkun Yang; Ruiyan Zhang
Journal:  Adv Ther       Date:  2020-03-07       Impact factor: 3.845

10.  Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography.

Authors:  Masaru Kuroda; Toshiro Shinke; Hiromasa Otake; Daisuke Sugiyama; Tomofumi Takaya; Hachidai Takahashi; Daisuke Terashita; Kenzo Uzu; Natsuko Tahara; Daiji Kashiwagi; Koji Kuroda; Yuto Shinkura; Yoshinori Nagasawa; Kazuhiko Sakaguchi; Yushi Hirota; Wataru Ogawa; Ken-Ichi Hirata
Journal:  Cardiovasc Diabetol       Date:  2016-05-21       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.